Why Investors Should Pay Attention To Psychedelics

Thanks to technological innovation and a better understanding of the human body, medicine has come a long way in the past few decades. In fact, serious ailments like hepatitis C and various forms of cancer that were previously thought to be incurable or untreatable now have treatments and cures on the market. 

While this innovation has led to a wide range of new effective therapies for a wide range of ailments, some companies are looking to the past for answers to the questions of today. 

Medicine Men May Have Been Onto Something 

For countless years, medicine men have used what would be considered an unorthodox approach to medicine today. Through the use of psychedelic compounds like psilocybin, a compound found in “magic mushrooms,” these healers that date back to ancient times treated patients with a wide range of ailments from depression to pain and more. 

However, recent research shows that these treatments were far more than snake oil.

In fact, one company, Silo Pharma Inc (OTCMKTS: SILO), is taking a page out of the ancient medicine man’s playbook and seeing tremendous results. The company is merging traditional medicine with psychedelic research in an attempt to develop therapeutics for a wide range of conditions, including but not limited to, fibromyalgia, cancer, post traumatic stress disorder (PTSD), and Parkinson’s disease.  

The company seems to be onto something too. In fact, while psychedelics haven’t been widely studied as therapeutic options, there have been a few studies that show these therapeutics can be effective. 

In 2013, the University of South Florida performed a study in 2013, giving low-dose psilocybin to mice in an attempt to alleviate conditioned fear. The study proved that the therapeutic option had a positive effect on the mouse population it was given to, but the eradication of conditioned fear wasn’t the most important finding. 

The study found that the compound worked by stimulating nerve cell growth in parts of the brain responsible for emotion and memory. This is meaningful data that suggests Silo Pharma may be on the right track in terms of using low-dose psilocybin as a potential therapeutic for Parkinson’s disease patients. 

Moreover, Dr. Stephen Ross, a psychiatrist at NYU Langone, conducted a study on terminally ill cancer patients in 2016. The goal was to provide relief from distress in the patient population, and that’s exactly what happened when low-dose psilocybin was introduced. In fact, the treatment proved to quickly bring relief from distress, relief that would last a minimum of six months for about 80% of the patient population. 

Considering these studies, Silo Pharma could be onto something big here. While “magic” mushrooms may be looked at as no more than a party aid for college students, the potential of these psychedelic fungi and the compounds within them in the field of medicine is hard to ignore. 

Final Thoughts

If you’re looking to make an investment in a company that’s on the ground floor of medical innovation, searching for therapeutics for patients with debilitating conditions, Silo is a great stock to consider. The fact of the matter is that the company’s use of psychedelics in a wide range of ailments follows centuries of medicine men having positive results. Granted, the company isn’t interested in giving high doses of psychedelics to patients as medicine men did, but modern research shows that doing so is largely unnecessary. 

Should all continue to go well for the company, it may produce therapies for a wide range of ailments that are considered difficult to treat, even with today’s modern medical approach. As such, the stock is well worth paying close attention to. 

Don't Miss the Next Big Story

Join our free mailing list below to receive real-time, actionable alerts!

Disclosure. CNA Finance is not a financial advisor or broker dealer. Trading in penny stocks can lead to a significant loss of capital. CNA Finance has a financial relationship with Silo Pharma.